At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 48 enrolled
Drug / intervention
BI 836826drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I, Open-Label, Dose-Escalation Trial With BI 836826 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma of B Cell Origin
In Brief
A Phase 1 clinical trial evaluating BI 836826 for Lymphoma, Non-Hodgkin. Completed, enrolled 48 participants across 12 sites in 3 countries.
Detailed Summary
The purpose is to investigate the maximum tolerated dose (MTD), safety and tolerability, pharmacokinetics and efficacy of BI 836826 monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma with at least prior treatments.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma, Non-Hodgkin
CountriesFrance, Germany, South Korea
Collaborators--
Timeline
Phase 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJul 2011
Enrollment StartAug 2011
Primary CompletionNov 2017
Study CompletionFeb 2018
TodayJul 2026
First PostedJul 27, 2011
Enrollment StartAug 1, 2011
Primary CompletionNov 14, 2017
Study CompletionFeb 28, 2018
TodayJul 2, 2026
Enrollment to primary: 6.3 yearsPosted 14.9 years ago
Interventions
BI 836826drug
Monotherapy with BI 836826 at escalating dose levels administered as an intravenous infusion